The Centers for Disease Control and Prevention (CDC) recommends pneumococcal conjugate vaccine for all children younger than 2 years old. Other vaccines for infants include, Hepatitis B vaccine, flu vaccine, and human papillomavirus vaccine.
The global pediatric vaccine market is estimated to account for US$ 37,567 Mn in terms of value in 2019 and is expected to reach US$ 98,859 Mn by the end of 2027.
Global Pediatric Vaccine Market: Drivers
Increasing funding related to vaccines is expected to boost growth of the global pediatric vaccines market over the forecast period. For instance, in January 2020, Codagenix, a company focused on R&D of vaccines and viral therapies raised US$ 20 million in a new round of financing led by Adjuvant Capital.
Global Pediatric Vaccine Market: Opportunities
Players in the market may focus on targeting developing regions for launching essential vaccines. The prevalence of tuberculosis is high in such regions. Moreover, increasing resistance of antibiotics used to treat tuberculosis is also expected to offer lucrative growth opportunities for players in the market.
Global Pediatric Vaccine Market: Restraints
Mistrust regarding vaccination is high in some countries, which is expected to hinder growth of the market. For instance, according to The Wellcome Trust’s Wellcome Global Monitor (2019), Gabon (26%), Togo (25%), Russia (24%), Austria (21%), and Iceland (21%) were the leading countries with mistrust of vaccine safety.
Pneumococcal Vaccine sub segment in the vaccine type segment in global pediatric vaccines market was valued at US$ 10,299.7 Mn in 2018 and is expected to reach US$ 36,120.1 Mn by 2027 at a CAGR of 14.4% during the forecast period.
Increasing partnership among Global Alliance for Vaccines and Immunization (GAVI) and key vendors to deliver pneumococcal vaccines in emerging countries is expected to be a significant growth factor for the market. For instance, in March 2016, GSK (Glaxo Smith Kline) announced the introduction of pneumococcal vaccine at the lowest price - US$ 3.05 from 2017, a reduction of 10% from the 2016 price (US$ 3.40).
The conjugate vaccines segment held dominant position in the global pediatric vaccine market in 2018, accounting for 30.0% share in terms of value, followed by live vaccines and inactivated vaccine, respectively.
Increasing approval for meningococcal conjugate vaccine candidates is expected to boost growth of the global conjugate vaccine market. For instance, in December 2016, Pfizer Inc. received an European Commission (EC) approval for its expanded indication for Nimenrix (meningococcal group A, C, W-135, and Y conjugate vaccine), which is indicated for active immunization against invasive meningococcal disease (IMD). Furthermore, development of multivalent conjugate vaccines by key players is expected to drive growth of global conjugate vaccine market. For instance, in September 2018, Pfizer, Inc. received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077.
The monovalent vaccines segment held dominant position in the global pediatric vaccine market in 2018, accounting for 76.6% share in terms of value, followed by multivalent vaccine, respectively.
Majority of the newely approved pediatric vaccines, as well as existing pediatric vaccines for different diseases are monovalent vaccines. Monovalent vaccines provide protection from an individual disease.
Major players in the market are focused on conducting clinical trials to expand their product portfolio. For instance, in November 2019, Takeda Pharmaceutical Company Limited announced publication of results from the primary endpoint analysis of its Phase 3 Tetravalent Immunization against Dengue Efficacy Study trial of its dengue vaccine candidate (TAK-003) in the New England Journal of Medicine.
Major players in the market are also focused on developing new vaccines. For instance, in November 2019, NewLink Genetics Corporation received the European Commission (EC) approval for marketing ERVEBO or Zaire Ebola virus vaccine V920 across 31 European countries.
Global Pediatric Vaccine Market: Competitive Landscape
Major players operating in the global pediatric vaccine market include GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., Sanofi, Pancea Biotec, Zydua Cadila, Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech, and Indian Immunologicals Ltd.
Global Pediatric Vaccine Market: Key Developments
December 2019: Y-mAbs Therapeutics Inc. received a Rare Pediatric Disease Designation status for its GD2-GD3 vaccine for the treatment of neuroblastoma, from the U.S. FDA
December 2019: Seqirus received approval for its cell-based quadrivalent influenza vaccine FLUCELVAX QUAD for the protection against four influenza virus strains — A(H3N2), A(H1N1) and two B virus strains, from Health Canada
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.